



(51) International Patent Classification:

C07D 453/02 (2006.01) **A61P 25/00** (2006.01)
C07D 471/08 (2006.01) **A61P 35/00** (2006.01)
A61K 31/439 (2006.01)

(21) International Application Number:

PCT/US2013/058896

(22) International Filing Date:

10 September 2013 (10.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/699,714 11 September 2012 (11.09.2012) US

(71) Applicant: GENZYME CORPORATION [US/US]; 500
Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **BOURQUE, Elyse**; 19 Malden Street, Watertown, Massachusetts 02472 (US). **CABRERA-SALAZAR, Mario, A.**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55-505A, Bridgewater, New Jersey 08807 (US). **CELATKA, Cassandra**; 23 Don Emerson Road, Chesterfield, Massachusetts 01012 (US). **CHENG, Seng, H.**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505a, Bridgewater, New Jersey 08807 (US). **HIRTH, Bradford**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **GOOD, Andrew**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **JANCSICS, Katherine**; 32 Hopkins, Wilmington, Massachusetts 01887 (US). **MARSHALL, John**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **METZ, Markus**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **SCHEULE, Ronald, K.**; c/o Sanofi, 55 Corporate, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **SKERLJ, Renato**; 13 Crocker Circle, Newton, Massachusetts 02465 (US). **XIANG, Yibin**; 24 Marshall Path, 24 Marshall Path, Acton, Massachusetts 01720 (US). **ZHAO, Zhong**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **LEONARD, John**; c/o

Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **NATOLI, Thomas**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **MAKINO, Elina**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **HUSSON, Herve**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **BESKROVNAYA, Oxana**; c/o Sanofi, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **SZCZEPANIK, Ann Marie** et al.; Sanofi U.S., 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

(57) Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

